Page 12 - Delaware Medical Journal - January 2016
P. 12
CANCER CLINICAL TRIAL
NCI PROTOCOL OF THE MONTH
Alliance A091201: Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
The objectives of the trial are: Primary Objective:
Compare the progression-free survival rate at 4 months (PFS4) of patients with ocular melanoma treated with cabozantinib or temozolomide (or dacarbazine).
Secondary Objectives:
1. Estimate the distribution of progression-free survival (PFS) times.
2. Estimate the distribution of overall survival (OS) times.
3.
4.
5.
Eligibilty:
prior to starting treatment with cabozantinib.
is longer).
No radiographic evidence of pancreatitis.
Treatment:
Arm 1 Cabozantinib:
Arm 2 Temozolomide:
Dacarbazine:
(Only if Temozolomide is not available for patient) (With permission of Alliance study chair)
to cross-over to the Cabozantinib arm.
For information regarding clinical trials
or if you would like to have the list of open protocols e-mailed to you, akee@christianacare.org.
12
Del Med J | January 2016 | Vol. 88
| No. 1
